title: Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity.
abstract: A case is reported of reversible sensorineural hearing loss associated with intravenous erythromycin treatment. Cis-platinum induced high frequency hearing loss developed nine months previously during treatment for stage IV papillary cystadenocarcinoma. Renal and hepatic function were normal; however, serum erythromycin levels were elevated. Clinical recovery promptly followed discontinuation of erythromycin.
authors: Department of Internal Medicine, University of South Florida College of Medicine, Tampa.
authors: P M
authors: PM
authors: Wallach
authors: S R
authors: SR
authors: Love
authors: J V
authors: JV
authors: Fiorica
authors: M S
authors: MS
authors: Hoffman
authors: M T
authors: MT
authors: Flannery
mesh_terms: D002945:Cisplatin / Q000009:adverse effects*; D003536:Cystadenocarcinoma / Q000188:drug therapy; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D005260:Female; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced*; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy
chemical_list: D004917:Erythromycin; D002945:Cisplatin